In this unique one-hour webinar, Dr. Jena outlines a broader framework for assessing value to improve identification of not only the highest-value treatments, but also low-value therapies on which spending can safely be reduced.
In a special feature focused on drug pricing solutions and value, PharmaLive’s Christiane Truelove talks with Precision subject matter experts Jeremy Schafer and Jason Shafrin, who offer their perspectives on the complex landscape.
As the spotlight on manufacturers’ raising the prices of therapies already on the market shows no sign of dimming, one industry group recently unveiled its intentions to dig a little deeper into the topic. The Institute for Clinical and Economic Review (ICER) says it will create a series of so-called Unsupported Price Increase (UPI) reports that will examine whether price increases are justified.
In a special commentary appearing in STAT News, Jacki Chou, Senior Director, Policy & Economics, and her co-author discuss overcoming 5 critical challenges in the US biosimilars marketplace, offering some strategic policy recommendations for the consideration of key healthcare stakeholders. […]
In the latest edition of the Journal of Clinical Pathways (JCP), Zachary Bessette summarizes PHE Senior Research Economist Jim Baumgardner’s recent ASH presentation, focused on studying the cost-effectiveness of novel CAR-T treatments. In the study, Dr. Baumgardner’s team asserts that the introduction of CAR-T therapies represents a major break from the trend of declining incremental effectiveness and provides similar cost-effectiveness to other innovations.
For more information, or to learn how to change your cookies preferences, please click here.